Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer Statistics, 2006. CA Cancer J Clin 2006; 56:106-30; PMID:16514137; http://dx.doi.org/10.3322/canjclin.56.2.106
   PubMed Web of Science ®Google Scholar
• O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96:1420-5; PMID:15467030; http://dx.doi.org/10.1093/jnci/djh275
   PubMed Web of Science ®Google Scholar
• Pihl E, Nairn R, Milne B, Cuthbertson A, Hughes E, Rollo A. Lymphoid hyperplasia: a major prognostic feature in 519 cases of colorectal carcinoma. Am J Pathol 1980; 100:469-80; PMID:7406021
   PubMed Web of Science ®Google Scholar
• Ohtani H. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 2007; 7:4; PMID:17311363
   PubMedGoogle Scholar
• Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997; 182(3):318-24; PMID:9349235; http://dx.doi.org/10.1002/(SICI)1096-9896(199707)182:3<318::AID-PATH862>3.0.CO;2-6
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (80) 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
   PubMed Web of Science ®Google Scholar
• Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353:2654-66; PMID:16371631; http://dx.doi.org/10.1056/NEJMoa051424
   PubMed Web of Science ®Google Scholar
• Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ontani1 H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58:3491-4; PMID:9721846
   PubMed Web of Science ®Google Scholar
• Prall F, Duehrkop T, Weirich V, Ostwald C, Lenz P, Nizze H, Barten M. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004; 35(7):808-16; PMID:15257543; http://dx.doi.org/10.1016/j.humpath.2004.01.022
   PubMed Web of Science ®Google Scholar
• Diederichsen ACP, Hjelmborg JVB, Christensen PB, Zeuthen J, Fenge C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 2003; 52:423-8; PMID:12695859; http://dx.doi.org/10.1007/s00262-003-0388-5
   PubMed Web of Science ®Google Scholar
• Menon AG, Janssen-van Rhijn CM, Morreau H, Putter H, Tollenaar RA, van de Velde CJH, Fleuren GJ, Kuppen PJK. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 2004; 84:493-501; PMID:14968119; http://dx.doi.org/10.1038/labinvest.3700055
   PubMed Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27:186-92; PMID:19064967; http://dx.doi.org/10.1200/JCO.2008.18.7229
   PubMed Web of Science ®Google Scholar
• Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, Von Knebel Doeberitz M, Folprecht G, Luber B et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 2011; 71:5670-7; PMID:21846824; http://dx.doi.org/10.1158/0008-5472.CAN-11-0268
   PubMed Web of Science ®Google Scholar
• Emile J, Mauer M, Tanis E, Julie C, Nordlinger B, Aust D, Roth A, Lutz MP, Gruenberger T, Wrba F et al. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. Eur J Cancer 2015; 51(17):2708-17; PMID:26342674; http://dx.doi.org/10.1016/j.ejca.2015.08.014
   PubMed Web of Science ®Google Scholar
• Halama N, Zoernig I, Spille A, Michel S, Kloor M, Grauling-Halama S, Westphal K, Schirmacher P, Jäger D, Grabe N. Quantification of prognostic immune cell markers in colorectal cancer using whole slide imaging tumor maps. Anal Quant Cytol Histol 2010; 32:333-40; PMID:21456345
   PubMed Web of Science ®Google Scholar
• Halama N, Spille A, Lerchl T, Brand K, Herpe E, Welte S, Keim S, Lahrmann B, Klupp F, Kahlert C et al. Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration. Oncoimmunology 2013; 2:e24116; PMID:23734335; http://dx.doi.org/10.4161/onci.24116
   PubMed Web of Science ®Google Scholar
• Halama N, Michel S, Kloor M, Zoernig I, Pommerencke T, Von M, Doeberitz K, Schirmacher P, Weitz J, Grabe N et al. The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun 2009; 9:1; PMID:19226101
   PubMedGoogle Scholar
• Wu AA, Drake V, Huang H-S, Chiu S, Zheng L. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology 2015; 4:e1016700; PMID:26140242; http://dx.doi.org/10.1080/2162402X.2015.1016700
   PubMed Web of Science ®Google Scholar
• Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F et al. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by Anti-CCR5 therapy in cancer patients. Cancer Cell 2016; 29:587-601; PMID:27070705; http://dx.doi.org/10.1016/j.ccell.2016.03.005
   PubMed Web of Science ®Google Scholar
• Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013; 339:286-91; PMID:23329041; http://dx.doi.org/10.1126/science.1232227
   PubMed Web of Science ®Google Scholar
• Findeisen P, Kloor M, Merx S, Sutter C, Woerner SM, Dostmann N, Benner A, Dondog B, Pawlita M, Dippold W et al. T25 repeat in the 3´untranslated region of the CASP2 gene: A sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Res 2005; 65:8072-8; PMID:16166278; http://dx.doi.org/10.1158/0008-5472.CAN-04-4146
   PubMed Web of Science ®Google Scholar
• Halama N, Zoernig I, Spille A, Westphal K, Schirmacher P, Jaeger D, Grabe N. Estimation of immune cell densities in immune cell conglomerates: An approach for high-throughput quantification. PLoS One 2009; 4:e7847; PMID:19924291; http://dx.doi.org/10.1371/journal.pone.0007847
   PubMed Web of Science ®Google Scholar
• R Development Core Team. R: A Language and Environment for Statistical Computing [Internet]. R Found Stat Comput. Vienna Austria 2015; Available from: http://www.r-project.org/; PMID:26321800
   PubMedGoogle Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Sci (New York, NY) 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
   Google Scholar
• Guidolin D, Nico B, Crivellato E, Marzullo A, Vacca A, Ribatti D. Tumoral mast cells exhibit a common spatial distribution. Cancer Lett 2009; 273(1):80-5; PMID:18774635; http://dx.doi.org/10.1016/j.canlet.2008.07.032
   PubMed Web of Science ®Google Scholar
• Valous NA, Lahrmann B, Halama N, Bergmann F, Jäger D, Grabe N. Spatial intratumoral heterogeneity of proliferation in immunohistochemical images of solid tumors. Med Phys 2016; 43:2936; PMID:27277043; http://dx.doi.org/10.1118/1.4949003
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27; PMID:16977338; http://dx.doi.org/10.1038/nri1936
   PubMed Web of Science ®Google Scholar
• Keim S, Zoernig I, Spille A, Lahrmann B, Brand K, Herpel E, Grabe N, Jäger D, Halama N. Sequential metastases of colorectal cancer immunophenotypes and spatial distributions of infiltrating immune cells in relation to time and treatments. Oncoimmunology 2012; 1:593-9; PMID:22934251; http://dx.doi.org/10.4161/onci.20179
   PubMed Web of Science ®Google Scholar
• Herman Fridman W, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Publ Gr 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245
   Web of Science ®Google Scholar
• Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N, Koch M, Weitz J, Kloor M, Zoernig I et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res 2011; 17:678-89; PMID:21325295; http://dx.doi.org/10.1158/1078-0432.CCR-10-2173
   PubMed Web of Science ®Google Scholar
• Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell 2015; 27:462-72; PMID:25858805; http://dx.doi.org/10.1016/j.ccell.2015.02.015
   PubMed Web of Science ®Google Scholar
• Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 2014; 105:1-8; PMID:24168081; http://dx.doi.org/10.1111/cas.12314
   PubMed Web of Science ®Google Scholar
• Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8:958-69; PMID:19029990; http://dx.doi.org/10.1038/nri2448
   PubMed Web of Science ®Google Scholar
• Kuang DM, Zhao Q, Peng C, Xu J, Zhang J-P, Wu C, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 2009; 206:1327-37; PMID:19451266; http://dx.doi.org/10.1084/jem.20082173
   PubMed Web of Science ®Google Scholar
• Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203:871-81; PMID:16606666; http://dx.doi.org/10.1084/jem.20050930
   PubMed Web of Science ®Google Scholar
• Schwartz M, Zhang Y, Rosenblatt JD. B cell regulation of the anti-tumor response and role in carcinogenesis. J Immunother Cancer 2016; 4(40):1–15; PMID:27437104; http://dx.doi.org/10.1186/s40425-016-0145-x
   PubMed Web of Science ®Google Scholar
• Berntsson J, Nodin B, Eberhard J, Micke P, Jirström K. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. Int J Cancer 2016; 139:1129-39; PMID:27074317; http://dx.doi.org/10.1002/ijc.30138
   PubMed Web of Science ®Google Scholar
• Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, Nelson BH. CD20+ tumor-infiltrating lymphocytes have an atypical CD27 - memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 2012; 18:3281-92; PMID:22553348; http://dx.doi.org/10.1158/1078-0432.CCR-12-0234
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Schlößer HA, Gryschok L, Malcher J, Wennhold K, Garcia-Marquez M, Herbold T, Neuhaus LS, Becker HJ, Fiedler A et al. Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. Oncotarget 2014; 5:4651-64; PMID:25026291; http://dx.doi.org/10.18632/oncotarget.1701
   PubMed Web of Science ®Google Scholar
• Lundgren S, Berntsson J, Nodin B, Micke P, Jirström K. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer. J Ovarian Res 2016; 9:21; PMID:27048364; http://dx.doi.org/10.1186/s13048-016-0232-0
   PubMed Web of Science ®Google Scholar
• Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truit M, Olson P et al. Bruton tyrosine kinase–Dependent immune cell cross-talk drives pancreas cancer. Cancer Discov 2016; 6:270-85; PMID:26715645; http://dx.doi.org/10.1158/2159-8290.CD-15-0827
   PubMed Web of Science ®Google Scholar
• Bromley SK, Peterson DA, Gunn MD, Dustin ML. Cutting edge: hierarchy of chemokine receptor and TCR signals regulating T cell migration and proliferation. J Immunol 2000; 165:15-9; PMID:10861029; http://dx.doi.org/10.4049/jimmunol.165.1.15
   PubMed Web of Science ®Google Scholar
• Geiger B, Bershadsky A, Pankov R, Yamada KM, Correspondence BG. Transmembrane extracellular matrix– cytoskeleton crosstalk. Nat Rev Mol Cell Biol 2001; 2:793-805; PMID:11715046; http://dx.doi.org/10.1038/35099066
   PubMed Web of Science ®Google Scholar
• Xia N, Thodeti CK, Hunt TP, Xu Q, Ho M, Whitesides GM, Westervelt R, Ingber DE. Directional control of cell motility through focal adhesion positioning and spatial control of Rac activation. FASEB J 2008; 22(6):1649-59; PMID:18180334; http://dx.doi.org/10.1096/fj.07-090571
   PubMed Web of Science ®Google Scholar
• Dangerfield J, Larbi KY, Huang MT, Dewar A, Nourshargh S. PECAM-1 (CD31) homophilic interaction up-regulates alpha6beta1 on transmigrated neutrophils in vivo and plays a functional role in the ability of alpha6 integrins to mediate leukocyte migration through the perivascular basement membrane. J Exp Med 2002; 196:1201-11; PMID:12417630; http://dx.doi.org/10.1084/jem.20020324
   PubMed Web of Science ®Google Scholar
• Feng Y, Chen X, Zhang X. Roles of PECAM-1 in cell function and disease progression. Eur Rev Med Pharmacol Sci 2016; 20(19):4082-8; PMID:27775789
   PubMed Web of Science ®Google Scholar
• Fornasa G, Groyer E, Clement M, Dimitrov J, Compain C, Gaston A-T, Varthaman A, Khallou-Laschet J, Newman DK, Graff-Dubois S et al. TCR stimulation drives cleavage and shedding of the ITIM receptor CD31. J Immunol 2010; 184:5485-92; PMID:20400708; http://dx.doi.org/10.4049/jimmunol.0902219
   PubMed Web of Science ®Google Scholar
• Van Houdt IS, Sluijter BJR, Moesbergen LM, Vos WM, De Gruijl TD, Molenkamp BG, Van Den Eertwegh AJM, Hooijberg E, Van Leeuwen PAM, Meijer CJLM et al. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer 2008; 123:609-15; PMID:18498132; http://dx.doi.org/10.1002/ijc.23543
   PubMed Web of Science ®Google Scholar
• Hillen F, Baeten CIM, Van De Winkel A, Creytens D, Van Der Schaft DWJ, Winnepenninckx V, Griffioen AW. Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunol Immunother 2008; 57:97-106; PMID:17602225; http://dx.doi.org/10.1007/s00262-007-0353-9
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu L, Gong C, Shi H, Zeng Y, Wang X. Prognostic significance of tumor-associated macrophages in solid tumor: A meta-analysis of the literature. PLoS One 2012; 7:e50946; PMID:23284651; http://dx.doi.org/10.1371/journal.pone.0050946
   PubMed Web of Science ®Google Scholar
• Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: The paradox of colorectal cancer. Cancer Immunol Immunother 2011; 60:909-18; PMID:21644034; http://dx.doi.org/10.1007/s00262-011-1046-y
   PubMed Web of Science ®Google Scholar